Dermatitis

Upadacitinib exhibited efficacy and a favorable benefit-risk profile for the long-term treatment of moderate to severe atopic dermatitis in adolescents, according to a study.

Roflumilast cream 0.15% showed high efficacy rates among patients aged 6 years and older with mild to moderate atopic dermatitis, according to a study.

The FDA has extended the target action date of its review of the supplemental new drug application for Vtama cream 1% for the treatment of atopic dermatitis in adults and children aged at least 2 years, Organon announced in a press release.

Dermavant Sciences presented full results from its long-term extension trial of Vtama cream 1% for the treatment of atopic dermatitis at the Fall Clinical Dermatology Conference, the company announced in a press release.

LEO Pharma presented full results from its long-term trial of Adbry for atopic dermatitis at the Fall Clinical Dermatology Conference, according to a company press release.

Nearly half of patients with head and neck atopic dermatitis who were treated with tralokinumab reported disease clearance after 9 months, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Zabalafin hydrogel clinically improved itch and quality of life among pediatric and adult patients with atopic dermatitis, according to interim results presented at the European Academy of Dermatology and Venerology Congress.

Orismilast outperformed placebo in the treatment of moderate to severe atopic dermatitis in adults, according to a poster presented at the European Academy of Dermatology and Venereology Congress.

New interim, long-term results showed that nemolizumab improved signs and symptoms of atopic dermatitis including sleep, itch and quality of life, according to a presentation at the European Academy of Dermatology and Venereology Congress.

Zoryve cream 0.15% continues to show that it can provide clinical improvement to patients with atopic dermatitis, according to a press release.